Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -111.42% is 16% below its 5-year average of -95.72%, near the high end of its 5-year range (-931.58%–-67.03%).
As of the fiscal period ended Tuesday, June 30, 2026. 27.39% below its 12-month average of -87.46%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -111.42%.
RETURN ON EQUITY (ROE)
-111.42%
RETURN ON EQUITY (ROE) AVG TTM
-87.46%
RETURN ON EQUITY (ROE) AVG 3Y
-89.31%
RETURN ON EQUITY (ROE) AVG 5Y
-95.72%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-27.39%
CURRENT VS 3Y AVG
-24.76%
CURRENT VS 5Y AVG
-16.40%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.30%
median of 612 covered companies
CURRENT VS SECTOR MEDIAN
-176.44%
vs the sector median at left
Lucyd, Inc
Market Cap
$5.85M
Return on Equity (ROE)
-111.42%
TTM Avg
-87.46%
3Y Avg
-89.31%
5Y Avg
-95.72%
Market Cap
$5.79M
Return on Equity (ROE)
-76.07%
TTM Avg
-61.76%
3Y Avg
-59.53%
5Y Avg
-66.20%
Market Cap
$5.94M
Return on Equity (ROE)
105.35%
TTM Avg
0.10%
3Y Avg
-37.77%
5Y Avg
-33.57%
Market Cap
$6.01M
Return on Equity (ROE)
-87.12%
TTM Avg
-90.45%
3Y Avg
-143.11%
5Y Avg
-272.17%
Market Cap
$5.66M
Return on Equity (ROE)
-92.44%
TTM Avg
-28.72%
3Y Avg
10.69%
5Y Avg
23.75%
Market Cap
$5.63M
Return on Equity (ROE)
-92.08%
TTM Avg
-1221.97%
3Y Avg
-730.41%
5Y Avg
-532.44%
Market Cap
$6.21M
Return on Equity (ROE)
-143.54%
TTM Avg
-132.34%
3Y Avg
-104.07%
5Y Avg
-91.90%
Market Cap
$6.31M
Return on Equity (ROE)
-304.78%
TTM Avg
-566.96%
3Y Avg
-321.57%
5Y Avg
-251.82%
Market Cap
$5.29M
Return on Equity (ROE)
-156.77%
TTM Avg
-655.11%
3Y Avg
-353.82%
5Y Avg
-293.10%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lucyd, Inc (LUCY) | $5.85M | -111.42% | -87.46% | -89.31% | -95.72% |
| enVVeno Medical Corporation (NVNO)vs › | $5.79M | -76.07% | -61.76% | -59.53% | -66.20% |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.94M | 105.35% | 0.10% | -37.77% | -33.57% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.01M | -87.12% | -90.45% | -143.11% | -272.17% |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.66M | -92.44% | -28.72% | 10.69% | 23.75% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | -92.08% | -1221.97% | -730.41% | -532.44% |
| Biomerica, Inc. (BMRA)vs › | $6.21M | -143.54% | -132.34% | -104.07% | -91.90% |
| Femasys Inc. (FEMY)vs › | $6.31M | -304.78% | -566.96% | -321.57% | -251.82% |
| Alzamend Neuro Inc (ALZN)vs › | $5.29M | -156.77% | -655.11% | -353.82% | -293.10% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.26M | -225.57% | -289.16% | -245.03% | -192.04% |
ROE
-111.4%
ROA
-102.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -111.42% |
| 2026-03-31 | -97.04% |
| 2025-12-31 | -83.73% |
| 2025-09-30 | -76.56% |
| 2025-06-30 | -68.56% |
| 2025-03-31 | -101.07% |
| 2024-12-31 | -85.39% |
| 2024-09-30 | -73.50% |
| 2024-06-30 | -107.09% |
| 2024-03-31 | -184.64% |
| 2023-12-31 | -119.87% |
| 2023-09-30 | -80.43% |
| 2023-06-30 | -67.03% |
| 2023-03-31 | -129.80% |
| 2022-12-31 | -141.18% |
| 2022-09-30 | -93.16% |
| 2021-06-30 | -931.58% |
